Followers | 35 |
Posts | 182 |
Boards Moderated | 0 |
Alias Born | 05/03/2020 |
![](https://investorshub.advfn.com/uicon/743282.png?cb=1588808426)
Friday, May 29, 2020 2:14:06 AM
Amgen is repurposing its Otesla drug to address respiratory illness as preventative therapy. Just like Bril, Ostela shares somewhat similar anti-inflammatory properties in inhibit PDE4. But Bril has more with its 3-in-1 action.
It's looking like Bril is an i-o platform with potentially treating AKI as well. This is a blockbuster drug in the making once we get results back and phase II gets going, IMO.
Two pathways so far: cAMP + IFnB. Lastly, my previous tweet a few weeks back to postulate how Bril exhibits its antiviral effects(2) was posted here as well and the recent pr confirmed it. We have a great science here in Bril!
My hypothesis is slightly different from Spike protein and SARsCoV2's cell membrane, which I referred the E -envelope that is a bilayer lipid membrane. In my previous contributions, I mentioned that Bril inhibits viral replications by ENTRY AND REPLICATION; and the MOA of actions will not only involve the virus wall membrane that most think here but it will also include the S-protein. The spike protein of SARScoV2 has always been the mediator of how the virus enters, infect, and induce the pathogenesis into the host cells. So S-protein structure consists of S1 AND S2, for receptor binding and for fusion, respectively, that interfaces with the human ACE2 protein receptor. This S-spike matches up well with Bril since both contain hydrophilic and hydrophobic regions. Bril amphipathic regions simply bind to S-protein. Like-to-like binding affinity molecules between Hydrophobic and hydrophilic. This is remarkable!
What happens next is your positive curvature (convex) change in the physicochemical properties of S-protein binding to Bril. So this distortion of the shape hinders S-protein ability to bind to ACE2 receptor into the host cells. That's your inhibition of antiviral via entry. The last one is inhibition by replication. This the portion where Bril's antimicrobial peptide degenerates, compromises, or melts the bilayer membrane (known as Envelope Protein or E- protein), to make the wall porous and creating a negative curvature that it ultimately inhibits RNA replication. Apoptosis happens!
But we shall see what UNIVERSITY top virologists say!
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM